Expand ACET Menu
ACET MENU

ACET Latest Press Releases

-- November 28, 2025 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 2:23 PM

-- November 5, 2025 --

Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- October 31, 2025 --

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:59 PM

-- October 28, 2025 --

Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference Business Wire 7:00 AM

-- October 16, 2025 --

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) Business Wire 7:00 AM

-- October 7, 2025 --

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering Business Wire 7:01 AM
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) Business Wire 6:45 AM

-- September 30, 2025 --

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:27 PM

-- September 2, 2025 --

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference Business Wire 7:00 AM

-- August 29, 2025 --

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:48 PM

-- August 7, 2025 --

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- August 5, 2025 --

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference Business Wire 7:00 AM

-- July 24, 2025 --

Adicet Bio Doses First Systemic Sclerosis Patient In Phase 1 Clinical Trial Of ADI-001 Benzinga Newsdesk 7:09 AM
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases Business Wire 7:00 AM
Market Data Delayed 15 Minutes